Viekirax Approval Set To Rattle Japan Hep C Market
This article was originally published in PharmAsia News
Executive Summary
AbbVie's all-oral, interferon- and ribavirin-free combination therapy for hepatitis C, Viekirax, has been approved in Japan, setting the stage for intensified competition in what is a large market.